The above findings suggested that the CD155/TIGIT signal axis could serve as the target for pancreatic cancer immunotherapy, especially in patients who do not respond to anti-PD-1 therapy, which is expected to improve the suppressive immune system microenvironment. The gene discussed is PDCD1; the disease is familial pancreatic carcinoma.